Glycyrrhizin

Phase 2Small molecule

MMansoura University

Glycyrrhizin is one of 36 small molecule programs targeting Medication. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MedicationNot yet recruiting

Prostate CancerRecruiting

MedicationPreclinical

Not yet recruiting

Prostate CancerPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

7 2

Antiandrogen Therapy

UUniversity of Washington

Phase 3

10 3

AAA817

Novartis

Phase 3

1 4

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 5

HC-1119

HHinova Pharmaceuticals Inc.

Phase 3

2 6

Trexall

Glycyrrhizin

1 8

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Prostate Cancer

NCT06378346

Q4 2027

N/ANot yet recruiting

Medication

NCT07236567

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

GU-01: Glycyrrhizin in Prostate Cancer

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT06378346·60 enrolled

Medication1 trial

Revascularization of Young Immature Permenant Teeth Using Different Types of Intra Canal Medication

Not yet recruiting·—·N/A·NCT07236567·45 enrolled

Randomized Controlled Trial1 trial

Molecular Analysis of Intracanal Microbes After Chemomechanical Procedure and Root Canal Medication: A Randomized Controlled Trial

Completed·MMansoura University·Phase 1·NCT06291623·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Glycyrrhizin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glycyrrhizin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glycyrrhizin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mansoura University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMansoura University

Glycyrrhizin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Prostate Cancer1 trial

Medication1 trial

Randomized Controlled Trial1 trial

References

Drug Info

Quick Facts

Related News